EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER

被引：0
|
作者：
Pinto, R. [1 ]
Monteiro, S. [1 ]
Lima, B. [2 ]
Lopes, A. R. [1 ]
Abreu, M. [1 ]
Ferreira, M. [1 ]
Sousa, S. [1 ]
Redondo, P. [1 ]
Pereira, D. [1 ]
Savva-Bordalo, J. [1 ]
机构：
[1] Portuguese Oncol Inst Porto, Porto, Portugal
[2] Hosp Senhora Oliveira, Creixomil, Portugal
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.465
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
759
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [31] RETRACTED: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma (Retracted Article)
    Sun, Li
    Liu, Caixia
    Li, Yun
    [J]. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [32] A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.
    WriQht, J. D.
    Alvarezsecord, A.
    Numnum, T. M.
    Rocconi, R. P.
    Powell, M. A.
    Berchuck, A.
    Alvarez, R. D.
    Trinkaus, K.
    Rader, J. S.
    Mutch, D. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 260S - 260S
  • [33] The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
    Barber, Emma L.
    Zsiros, Emese
    Lurain, John R.
    Rademaker, Alfred
    Schink, Julian C.
    Neubauer, Nikki L.
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (03) : 258 - 264
  • [34] CABAZITAXEL - A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
    Madsen, C. V.
    Adimi, P.
    Jakobsen, A.
    Dahl, S. Karina
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 722 - 722
  • [35] Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer
    Liu, Biao
    An, Ran
    Yu, Jianwei
    [J]. JOURNAL OF BUON, 2019, 24 (06): : 2303 - 2309
  • [36] Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial
    Tomao, Federica
    Tomao, Silverio
    Panici, Pierluigi Benedetti
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) : 3580 - 3580
  • [37] Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer
    Madsen, Christine Vestergaard
    Adimi, Parvin
    Jakobsen, Anders
    Steffensen, Karina Dahl
    [J]. ANTICANCER RESEARCH, 2020, 40 (09) : 5255 - 5261
  • [38] Clinical and pharmacodynamic activity of decitabine in vivo for patients with recurrent, platinum-resistant, epithelial ovarian cancer
    Fang, Fang
    Balch, Curt
    Schilder, Jeanne
    Zhang, Shu
    Shen, Changyu
    Li, Lang
    Snyder, Anthony
    Nephew, Kenneth
    Matei, Daniela
    [J]. CANCER RESEARCH, 2009, 69
  • [39] Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer
    Le, T.
    Hopkins, L.
    Baines, K. A.
    Rambout, L.
    Al Hayki, M.
    Fung, M. Kee Fung
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 102 (01) : 49 - 53
  • [40] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345